Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
Agensys
Download detailed PDF Members: Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less severe side effects. All of Agensys' cancer targets must meet the following criteria: (1) a novel molecule and/or a novel utility in cancer; (2) expression in a significant percentage of patients' specimens; (3) limited expression in normal vital tissues; and (4) structural and functional features suitable for therapeutic intervention. The Company is generating fully human antibodies to multiple targets from its portfolio, including those directed to prostate, kidney, bladder, colon, lung, ovary and pancreatic cancers. The Company's portfolio also contains multiple validated targets for small molecule and vaccine products that it intends to develop through partnerships with pharmaceutical and biotechnology companies.
This page has been viewed 521 times since April 2007, the link to the organisation's website has been followed 80 times Recent Search Terms used to find this page: monoclonal antibodies ags 1c4d4 | agensys | HIFU press releases | Steap 1 mabs agensys | Agensys, Inc | Agensys | agensys 1545 17th Street Santa Monica CA 90404 | agensys | . Search for more companies in Santa Monica Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Agensys | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|